Merit Medical’s PReSeRVE-HD Study: A Promising Step for Dialysis Patients

Merit Medical ((MMSI)) announced an update on their ongoing clinical study.

Study Overview: The PReSeRVE-HD study, officially titled ‘PRospective, Multicenter, Observational Study of the Merit HeRO® Graft and Super HeRO® EValuated in End-Stage Renal Disease Patients on HemoDialysis,’ aims to evaluate the safety and performance of the HeRO® Graft System and Super HeRO® devices in patients with end-stage renal disease undergoing hemodialysis. This study is significant as it seeks to improve long-term dialysis access for patients when other options have failed.

Intervention/Treatment: The study focuses on the HeRO® Graft System and Super HeRO® System, which are devices designed to maintain dialysis access in patients with end-stage renal disease. These devices are intended to provide a reliable solution for patients who have exhausted other dialysis access options.

Study Design: This is an observational, prospective cohort study that will follow patients over two years. Participants are observed in their natural settings without any allocation or masking, focusing on understanding the real-world performance of the devices.

Study Timeline: The study began on May 15, 2024, with the latest update submitted on July 31, 2025. These dates are crucial as they indicate the study’s progression and ongoing recruitment status, which is essential for tracking its impact and results.

Market Implications: Merit Medical’s ongoing study could positively influence its stock performance by demonstrating the effectiveness of its HeRO® devices, potentially boosting investor confidence. As the company seeks to address a critical need in dialysis access, successful outcomes could position it favorably against competitors in the medical device industry.

The PReSeRVE-HD study is currently recruiting, with further details available on the ClinicalTrials portal.